Acadia Healthcare Company, Inc. Announces Second Quarter 2026 Results
Key Highlights from the Q2 2026 Report
- Revenue for Q2 2026: \$869.2 million
- Reported Net Income: \$10.9 million for Q2 2026
- Adjusted EBITDA: \$149.2 million for Q2 2026, down from \$201.8 million Q2 2025 (26% decrease)
- Reported Earnings Per Share (EPS): \$0.12 for Q2 2026
- Adjusted EPS: \$0.38 for Q2 2026, compared to \$0.83 Q2 2025
- 2026 Financial Guidance (Updated July):
- Revenue: \$3.40 to \$3.45 billion (narrowed upward from April’s \$3.37 to \$3.45 billion)
- Adjusted EBITDA: \$590 to \$615 million (raised from April’s \$580 to \$615 million)
- Adjusted EPS: \$1.45 to \$1.60 (up from \$1.35 to \$1.60)
- Operating Cash Flow: \$350 to \$400 million (significantly increased from \$285 to \$325 million)
- Capital Expenditures: \$235 to \$255 million (reduced from April’s \$255 to \$280 million)
- Conference Call: Company held a conference call to discuss Q2 results, and webcast/slide materials are available on the website for 30 days.
Detailed Financial Performance
Acadia Healthcare Company saw quarterly revenue of \$869.2 million, a modest increase over the prior year. However, adjusted EBITDA saw a notable decline of 26% year-over-year, falling from \$201.8 million in Q2 2025 to \$149.2 million this quarter. Net income similarly dropped, coming in at \$10.9 million for the quarter, compared to \$30.1 million in the prior year period. The reported EPS was \$0.12, while adjusted EPS was \$0.38, down significantly from \$0.83 in Q2 2025.
Balance Sheet Overview
- Total Assets: \$5,546,325,000 as of June 30, 2026
- Total Equity: \$1,979,122,000
- Long-Term Debt Borrowings: \$1.2 billion for the six months ended June 30, 2026
- Other Key Liabilities: Other liabilities at \$218.8 million; Redeemable noncontrolling interests at \$212.7 million
Cash Flow Analysis
- Operating Cash Flow: \$350 to \$400 million guidance for 2026 (up from earlier \$285 to \$325 million)
- Net cash used in investing activities: (\$92.9 million) for the six months ended June 30, 2026
- Net cash used in financing activities: (\$92.7 million) for the same period
- Capital Expenditures: Guidance now at \$235 to \$255 million for 2026, lower than prior guidance
Forward-Looking Statements and Guidance Update
The Company raised its full-year guidance in multiple areas, signaling stronger performance expectations for the remainder of 2026:
- Revenue outlook narrowed to \$3.40-\$3.45 billion, suggesting confidence in achieving higher sales.
- Adjusted EBITDA guidance increased to \$590-\$615 million, indicating improved profitability expectations despite recent quarterly declines.
- Adjusted EPS guidance raised to \$1.45-\$1.60, which may be seen as a positive for shareholders, since it reflects management’s optimism about earnings recovery in the coming quarters.
- Operating cash flow guidance increased substantially, suggesting enhanced liquidity and financial flexibility for investments or shareholder returns.
- Capital expenditures guidance is lowered, potentially indicating efficiency improvements or a more disciplined approach to spending.
These guidance updates are important for investors and may be price sensitive, especially given the Company’s confidence in higher revenue, EBITDA, and cash flow projections.
Potential Price-Sensitive Issues
- Decline in Adjusted EBITDA and EPS: The significant year-over-year drop in profitability metrics may raise concerns about operational challenges or margin pressures.
- Increase in Guidance: Management’s raised outlook for the full year could offset investor concerns about recent quarterly weakness, potentially supporting share price.
- Balance Sheet Changes: Large borrowings on long-term debt and revolving credit facility suggest ongoing investments or refinancing activities. Investors should monitor leverage and interest expense trends.
- Impairment and Transaction Costs: The report includes impairment losses and transaction/legal costs, which may impact net income and should be watched for future quarters.
- Cybersecurity and Regulatory Risks: The report cautions about risks such as cybersecurity incidents, labor cost increases, and regulatory changes (e.g., Medicaid work requirements), all of which could affect future operations and financial results.
Shareholder Information and Conference Call Details
Shareholders are encouraged to review the webcast and investor materials provided by Acadia Healthcare for further insights. The conference call recording and slides are available for 30 days on the Company’s website, offering deeper context for the financial results and future outlook.
Cautionary Note on Forward-Looking Statements
Acadia Healthcare’s report contains forward-looking statements regarding strategy, growth, and anticipated operating results. While management has raised guidance, risks remain, including debt servicing, labor costs, IT disruptions, and regulatory changes. Investors should consult the Company’s SEC filings for a comprehensive discussion of risk factors.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Financial figures are based on Acadia Healthcare Company, Inc.’s Q2 2026 SEC filings and press releases. Investors are encouraged to review the original filings and consult their financial advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties.
